|
|
|
|
|
|
|
|
|
|
|
|
|
<TABLE> <S> <C>
<ARTICLE> 5
<LEGEND>
This schedule contains summary financial information extracted from the BioCryst
Pharmaceuticals, Inc. Financial Statements, and is qualified in its entirety by
reference to such financial statements.
</LEGEND>
<S> <C>
<PERIOD-TYPE> 9-MOS
<FISCAL-YEAR-END> Dec-31-2000
<PERIOD-END> Sep-30-2000
<CASH> 8,774,555
<SECURITIES> 59,698,971
<RECEIVABLES> 0
<ALLOWANCES> 0
<INVENTORY> 0
<CURRENT-ASSETS> 26,450,709
<PP&E> 5,226,548
<DEPRECIATION> 2,403,160
<TOTAL-ASSETS> 72,375,439
<CURRENT-LIABILITIES> 932,514
<BONDS> 0
0
0
<COMMON> 175,361
<OTHER-SE> 71,142,925
<TOTAL-LIABILITY-AND-EQUITY> 72,375,439
<SALES> 0
<TOTAL-REVENUES> 7,912,337
<CGS> 0
<TOTAL-COSTS> 0
<OTHER-EXPENSES> 9,689,456
<LOSS-PROVISION> 0
<INTEREST-EXPENSE> 2,823
<INCOME-PRETAX> (1,779,942)
<INCOME-TAX> 0
<INCOME-CONTINUING> 0
<DISCONTINUED> 0
<EXTRAORDINARY> 0
<CHANGES> 0
<NET-INCOME> (1,779,942)
<EPS-BASIC> (.10)
<EPS-DILUTED> (.10)
</TABLE>
|
|